Apremilast
3 NDCs across 1 manufacturer|0 Generic,3 Brand
Apremilast is used to treat psoriatic arthritis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Mar 21, 2014, and the first generic was approved Feb 17, 2021. FDA's Orange Book lists 18 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $1.0 billion on Apremilast across 213,000 claims for 31,000 beneficiaries.
Apremilast is available as 3 NDCs from 1 manufacturer (0 generic, 3 brand), with NADAC prices from $89.95 to $98.55 per EA — a 10% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
3
0G / 3B
Manufacturers
1
competing in market
Price Spread
$89.95 – $98.55
per EA
7d Activity
avg +0.0% WoW · of 3 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Amgen Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Phosphodiesterase 4 Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing APREMILAST
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
OTEZLA 10-20-30 MG START 28 DAY | $98.5508 per EA | — |
OTEZLA 30 MG TABLET | $90.5717 per EA | +0.03% |
OTEZLA 20 MG TABLET | $89.9522 per EA | — |
Frequently Asked Questions
What is Apremilast used to treat?
Apremilast is used to treat psoriatic arthritis, per the National Library of Medicine's MED-RT classification.
When did Apremilast become available as a generic?
FDA approved the first generic Apremilast (ANDA) on Feb 17, 2021. The Orange Book currently lists 18 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Apremilast?
In 2024, Medicare Part D spent $1.0 billion on Apremilast across 213,000 claims for 31,000 beneficiaries.
How many Apremilast products are on the market?
The Apremilast drug market contains 3 NDCs from 1 manufacturer — 0 generic and 3 brand products.
What is the price range for Apremilast?
NADAC reference prices for Apremilast range from $89.9522 to $98.5508 per EA — a 10% difference between cheapest and most expensive.
Which manufacturers make Apremilast?
1 manufacturer lists Apremilast in NADAC. Ranked by number of NDCs, the largest are Amgen Inc. (3).
How has the price of Apremilast changed recently?
Over the past 7 days, 1 Apremilast NDC rose and 0 fell, with a market-wide average change of +0.0%.